Egrifta (Tesamorelin) Legal and Patent Challenges: FDA Approval, Labeling, and Safety

HealthRX.com

Egrifta's only approved use is abdominal fat in HIV lipodystrophy

1.4 mgDaily dose of Egrifta SV, given once daily into the abdomenSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 1.28 mgDaily dose of Egrifta WR, given once dailySource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 47%Share of patients on treatment whose IGF-1 rose above 2 SDSSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 25%Share of tesamorelin patients with injection site reactions in first 26 weeks, versus 14% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • First FDA approval / November 10, 2010, application 022505
  • Application status / Former new drug application, deemed a BLA on March 23, 2020
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy
  • Current labels / Egrifta SV 2 mg vial; Egrifta WR 11.6 mg vial, both July 29, 2026
  • Daily dose / SV 1.4 mg; WR 1.28 mg; not substitutable
  • Sport status / WADA S2.2.4, prohibited at all times

What did FDA approve?

Egrifta (tesamorelin acetate) was approved on November 10, 2010 under application 022505 [1]. Drugs@FDA records that the former new drug application was deemed a biologic license application on March 23, 2020, and lists 1 mg and 2 mg per vial products, both prescription, with no therapeutic equivalence code [1]. Today's products are Egrifta SV, dosed at 1.4 mg (0.35 mL) subcutaneously into the abdomen once daily, and Egrifta WR, dosed at 1.28 mg (0.16 mL) once daily; the labels say the two are not substitutable [2][3].

What the approved use covers

The only approved use is reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [2][3]. Both labels state that long-term cardiovascular safety has not been established, that the risk and benefit of continuing should be weighed in patients who have not lost visceral adipose tissue, that the drug is not indicated for weight loss management because its effect on weight is neutral, and that there are no data to support improved adherence to antiretroviral therapy [2][3]. Tesamorelin is a peptide that stimulates the pituitary to release the body's own growth hormone, not growth hormone itself [2].

What the labels tell prescribers to watch

Neither current label carries a boxed warning [2][3]. Contraindications in both are disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2][3]. The labels direct IGF-1 monitoring and say to consider discontinuing with persistent elevations, for example above 3 SDS, particularly when fat loss is not robust; among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [2]. Injection site reactions occurred in 25% on tesamorelin versus 14% on placebo during the first 26 weeks, and hypersensitivity reactions in 4% of treated patients [2].

Questions worth asking

Choose the questions you want to keep

Compounding and sport

Tesamorelin appears in no category of FDA's list of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026), and in no category of FDA's lists for state-licensed pharmacies and physicians (updated May 14, 2026) or for outsourcing facilities (updated March 21, 2025) [4][5][6]. It is not among the six peptides in HHS's draft enforcement-discretion policy for compounding [7][8]. WADA names tesamorelin in S2.2.4 among growth hormone releasing factors; S2 substances are prohibited at all times and are non-Specified Substances [9][10].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Do the current Egrifta labels carry a boxed warning?

Question 1 of 3

Score: 0 right, 0 of 3 answered

When was Egrifta approved?
FDA first approved Egrifta (tesamorelin acetate) on November 10, 2010 under application 022505 [1]. Drugs@FDA records that the former new drug application was deemed a biologic license application on March 23, 2020 [1].
Is tesamorelin approved for weight loss?
No. The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and the label states it is not indicated for weight loss management because its effect on weight is neutral [2][3].
What contraindications appear in the current labels?
Disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or the excipients, and pregnancy [2][3].
What does the FDA record show for application 022505?
The Drugs@FDA record for application 022505 lists the Egrifta 1 mg and 2 mg vials as prescription products with no therapeutic equivalence code [1].
Can tesamorelin be compounded?
FDA has made no category-based statement about it. Tesamorelin is not on its list of bulk substances that may present significant safety risks when compounded and appears in no category of its lists for state-licensed pharmacies and physicians or for outsourcing facilities, and it is not among the six peptides in the HHS draft policy [4][5][6][7][8].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Did the FDA approve Tesamorelin?

Yes. FDA first approved Egrifta (tesamorelin acetate) on November 10, 2010 under application 022505. The only approved use is reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and the label states the drug is not indicated for weight loss management.

Is Tesamorelin generic?

Tesamorelin is marketed under the brand name Egrifta. The Drugs@FDA record for application 022505 lists the Egrifta 1 mg and 2 mg vials as prescription products with no therapeutic equivalence code. Today's products are Egrifta SV and Egrifta WR, which the labels say are not substitutable.

How long has Tesamorelin been on the market?

FDA first approved Egrifta (tesamorelin acetate) on November 10, 2010, and the drug has been approved since then. The current Egrifta SV and Egrifta WR labels are both dated July 29, 2026. No total number of years on the market is stated.

Show all 10 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. Official web page.
  8. Official web page.
  9. World Anti-Doping Agency.
  10. World Anti-Doping Agency.
Evidence overview for Egrifta (Tesamorelin) Legal and Patent Challenges: FDA Approval, Labeling, and Safety